CA-ESRI
17.12.2021 22:02:10 CET | Business Wire | Press release
The global population grew by almost two billion people during the last 20 years—nearly 30 percent. Such growth is not evenly distributed over time or across space: the extremes include Qatar growing by 400 percent and Lithuania losing 25 percent. And even within countries, the rate of growth varies. To support the need for up-to-date population data that reflects these shifts, WorldPop and Esri , the global leader in location intelligence, have partnered to include WorldPop's 1-km annual gridded demographic datasets in ArcGIS Living Atlas of the World. The data covers 241 countries, territories, and dependencies for the 2000–2020 period.
"These datasets are critical for measuring and monitoring the accompanying sociodemographic changes over time and properly informing and supporting environmental, health, and development applications at local, subnational, national, and regional levels," said Professor Andrew Tatem, Director of WorldPop at the University of Southampton. "In this context, comparable, multitemporal, and spatially explicit detailed population distribution datasets are a fundamental prerequisite for communicating the impacts of population growth."
ArcGIS Living Atlas of the World is Esri's evolving collection of ready-to-use and up-to-date authoritative content in the form of maps, apps, and data layers—all accessible via a web browser and most Esri products.
"Having the WorldPop 1-km gridded demographic datasets available as imagery layers in ArcGIS Living Atlas of the World provides unprecedented convenience to query and analyze population anywhere on Earth," said Charlie Frye, Esri chief cartographer. "That these datasets no longer need to be downloaded or preassembled prior to use will result in substantial time and cost savings for any organization needing to understand recent population changes."
Queries can include the entire 21-year history of population changes for any group, including births and five-year age cohorts. The results of these queries can be spatiotemporally analyzed using Esri's ArcGIS software to find patterns. Multitemporal datasets depict grid cell level spatial distribution of total population, age, and sex cohorts and population density.
"The age and sex gridded datasets provide invaluable information about the spatial and temporal distribution of specific demographic groups, such as children, seniors, and women of childbearing age, which are well-known to be more vulnerable than others, and thus should be explicitly considered in decision- and policy-making processes," said Dr. Alessandro Sorichetta, Associate Professor in Applied Geospatial Research at WorldPop.
The 1-km raster layers, curated by the WorldPop Spatial Data Infrastructure Team led by Dr Maksym Bondarenko, are available in ArcGIS Living Atlas of the World for population per grid cell , population density per grid cell , and population by age and sex per grid cell .
To learn more about ArcGIS Living Atlas of the World and other Esri population data layers, please visit go.esri.com/livingatlas .
About WorldPop
WorldPop, initiated in October 2013 at the University of Southampton, develops methods and applications to produce open and high-resolution geospatial datasets on population distribution, demographics, and dynamics, with a focus mainly on low- and middle-income countries, to support development, disaster-response, and health applications. WorldPop research activities are designed with full open access and operational application in mind, using transparent, fully documented and peer-reviewed methods, to produce easily updatable outputs with accompanying metadata and, where possible, measures of uncertainty. WorldPop's work contributes to and benefits from direct engagement with multiple national statistical offices, national and international agencies, universities, research centers, and large international humanitarian donors, producing rapid and strong impacts from its research. WorldPop's population datasets and analyses inform several regional and global flagship reports and are the default geospatial demographic datasets used by many governments, international organizations, UN agencies, and private companies around the World. To learn more, visit our website and/or follow us on Twitter .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211217005617/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
